Diabetic Foot Infection Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
NCT number | NCT05369052 |
Other study ID # | MRXC-302 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 3, 2022 |
Est. completion date | June 2024 |
Verified date | May 2023 |
Source | MicuRx |
Contact | Clinical coordinator |
Phone | 510-782-2022 |
info[@]micurx.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Status | Recruiting |
Enrollment | 865 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have diabetes mellitus (type 1 or 2) per the American Diabetes Association criteria - Have a foot infection that started at or below the malleolus and does not extend above the knee - Foot infection that meets the IWGDF DFI criteria for classification 3 (moderate infection) or 4 (severe infection) - Foot infection had acute onset or worsening of signs and symptoms within the past 14 days Exclusion Criteria: - Previous DFI known or suspected to be caused by Gram-positive pathogens that are resistant to oxazolidinone antibiotics - DFI with presumptive evidence or suspicion of osteomyelitis - Necrotizing fasciitis, crepitant cellulitis, wet gangrene, gas gangrene, ecthyma gangrenosum, septic arthritis, or severely impaired arterial supply to any portion of the affected foot which may need revascularization before the end of the study - Evidence of significant hepatic, renal, hematologic, or immunologic disease - Females who are pregnant or breastfeeding - Prior receipt of any formulation of contezolid acefosamil or contezolid - Inability to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be noncompliant with any study requirements, or the Investigator determines that the subject should not participate in the study |
Country | Name | City | State |
---|---|---|---|
Bulgaria | MHAT Blagoevgrad AD, Department of Surgery | Blagoevgrad | |
Bulgaria | UMHAT - Sveti Georgi EAD | Plovdiv | |
Bulgaria | Multiprofile Hospital for Active Treatment - KANEV | Ruse | |
Bulgaria | Medical Institute Ministry of Interior Central Clinical Base | Sofia | |
Bulgaria | UMHAT - Sofiamed | Sofia | |
Bulgaria | UMHAT - Prof. Stoyan Kirkovich | Stara Zagora | |
China | West China Hospital | Chengdu | Sichuan |
China | Chongqing No. 4 People's Hospital | Chongqing | Sichuan |
China | The Second Affiliated Hospital of Chongqing Medical University | Chongqing | Sichuan |
China | Hainan Medical College No. 2 Affiliated Hospital | Haikou | Hainan |
China | Affiliated Hospital of Yunnan University | Kunming | Yunnan |
China | Zhongda Hospital Southeast University | Nanjing | Jiangsu |
China | The Second Affiliated Hospital of Guangxi Medical University | Nanning | Guangxi |
China | The Second Affiliated Hospital of Shantou University Medical Center | Shantou | Guangdong |
China | The First Hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | Chu Hsien-I Memorial Hospital of Tianjin Medical University | Tianjing | Tianjin |
China | The Central Hospital of Wuhan | Wuhan | Hubei |
China | Union Hospital Tongji Medical College Huazhong University | Wuhan | Hubei |
China | Xi'an Medical University First Affiliated Hospital | Xi'an | Shaanxi |
China | Affiliated Hospital of Jiangsu University | Zhenjiang | Jiangsu |
Estonia | Ida-Viru Central Hospital | Kohtla-Järve | |
Estonia | Tartu University Hospital | Tartu | |
Estonia | Viljandi Hospital | Viljandi | |
Estonia | South-Estonian Hospital Ltd. | Võru | |
Greece | General Hospital of Athens-Laiko | Athens | |
Italy | AORN - Ospedali dei Colli - Ospedale D. Contugno | Napoli | |
Latvia | Daugavpils Regional Hospital | Daugavpils | |
Latvia | Riga East Clinical University Hospital | Riga | |
Lithuania | Hospital of Lithuanian University of Health Sciences | Kaunas | |
Lithuania | Vilnius University Hospital Santaros Klimkos | Vilnius | |
Portugal | Hospital de CUF Descobertas Lisboa | Lisboa | |
Puerto Rico | Clinical Research Management Group, Inc. | Mayagüez | |
Spain | Hospital del Mar | Barcelona | |
United States | Billings Clinic Research | Billings | Montana |
United States | Velocity Clinical Research | Chula Vista | California |
United States | New Hope Research Development | Corona | California |
United States | Sacramento VA Medical Center | Mather | California |
United States | University Medical and Research Center, LLC | Miami | Florida |
United States | Floridian Clinical Research, LLC | Miami Lakes | Florida |
United States | Perseverance Research Center. LLC | Scottsdale | Arizona |
United States | South Jersey Infectious Disease | Somers Point | New Jersey |
United States | Harbor-UCLA Medical Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
MicuRx |
United States, Bulgaria, China, Estonia, Greece, Italy, Latvia, Lithuania, Portugal, Puerto Rico, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators | The primary objective is to evaluate the Investigator's assessment of clinical response at the D35 visit in subjects receiving contezolid acefosamil/contezolid compared to subjects receiving linezolid in the MITT analysis | Day 35 | |
Primary | Adverse events - symptoms reported by subjects | Evaluate safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) | 28-35 days after End-of-Therapy (EOT) | |
Primary | Clinical laboratory assessment - complete blood count | Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) | 28-35 days after End-of-Therapy (EOT) | |
Primary | Vital signs - heart rate | Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) | 28-35 days after End-of-Therapy (EOT) | |
Secondary | Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators | Evaluate the Investigator's assessment of clinical response at EOT visit in the MITT analysis set | 14-28 days | |
Secondary | Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators | Evaluate the Investigator's assessment of clinical response at Day 10 (D10) and Late Follow-Up visits (LFU; 28-35 days after EOT) in the MITT analysis set | Day 10, 28-35 days after EOT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Recruiting |
NCT05613985 -
PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers
|
N/A | |
Recruiting |
NCT03964571 -
Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients
|
N/A | |
Completed |
NCT03230175 -
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
|
Phase 2 | |
Completed |
NCT05616351 -
Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
|
||
Recruiting |
NCT05948592 -
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
|
Phase 2 | |
Recruiting |
NCT04714411 -
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
|
||
Completed |
NCT05243810 -
EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers
|
N/A | |
Recruiting |
NCT05610865 -
Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers
|
Phase 1 | |
Recruiting |
NCT04450693 -
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
|
Phase 3 | |
Completed |
NCT02723539 -
A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI
|
Phase 1 | |
Completed |
NCT04440839 -
Implementation of Telemedicine for Patient With Lower Extremity Wounds
|
N/A | |
Withdrawn |
NCT04289948 -
Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03495349 -
Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
|
||
Completed |
NCT05564728 -
Diabetes Footcare Companion App for Patients and Carers
|
||
Withdrawn |
NCT03354806 -
Peripheral Analgesia in Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT01594762 -
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
|
Phase 3 | |
Completed |
NCT01590758 -
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
|
Phase 3 | |
Active, not recruiting |
NCT05174806 -
Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients
|
Phase 2 | |
Recruiting |
NCT04141787 -
Ceftriaxone as Home IV for Staph Infections
|
Phase 4 |